Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Efficacy and Safety Trial With Intravenous S95011 in Primary Sjögren's Syndrome Patients: An International, Multicentre, Randomised, Double-blind, Placebo-controlled Study

NCT04605978 is registered in ClinicalTrials.gov with Institut de Recherches Internationales Servier as lead sponsor.

NCT NCT04605978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04605978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Efficacy and Safety Trial With Intravenous S95011 in Primary Sjögren's Syndrome Patients: An International, Multicentre, Randomised, Double-blind, Placebo-controlled Study
Lead sponsor
Institut de Recherches Internationales Servier
Phase
Phase 2
Overall status
Completed
Start date
August 3, 2021
Completion date
May 9, 2023
Enrollment
48 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

primary sjögren's syndrome